BridgeBio Pharma, Inc.

BBIO 10-K · FY 2025
API behind this page

BBIO FY 2025 request

Playground key active
Request URL /api/financials?ticker=BBIO&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 502,076 221,902 +126.3%
Show Product Lines breakouts
Cost of license, services, and royalty revenue · Bayer 93.8 — —
License And Service 128,322 218,849 -41.4%
License And Service · Alexion License Agreements 33.3 0.6 +5450.0%
License And Service · Kyowa Kirin Co., Ltd 12.3 76.2 -83.9%
License And Service · Reportable Segment 128,322 218,849 -41.4%
Product 362,368 2,884 +12464.8%
Product · Bayer 7.6 — —
Product · Reportable Segment 362,368 2,884 +12464.8%
Royalty 11,386 169 +6637.3%
Royalty · Reportable Segment 11,386 169 +6637.3%
Show Business Segments breakouts
Reportable Segment 502,076 221,902 +126.3%
Cost of Revenue 20,962 3,878 +440.5%
Show Product Lines breakouts
Cost of license, services, and royalty revenue 5,275 2,436 +116.5%
Cost of license, services, and royalty revenue · Reportable Segment 5,275 2,436 +116.5%
Product 15,687 1,442 +987.9%
Product · Reportable Segment 15,687 1,442 +987.9%
Show Business Segments breakouts
Reportable Segment 20,962 3,878 +440.5%
Research & Development 451,953 506,461 -10.8%
Show Business Segments breakouts
Reportable Segment 451,953 506,461 -10.8%
Reportable Segment · Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant 116,844 164,782 -29.1%
Reportable Segment · BBP-418 for LGMD2I/R9 56,008 40,220 +39.3%
Reportable Segment · Encaleret for ADH1 59,955 49,091 +22.1%
Reportable Segment · Infigratinib for achondroplasia and hypochondroplasia 122,685 91,869 +33.5%
Reportable Segment · Other development programs 22,703 71,732 -68.4%
Reportable Segment · Other research programs 73,758 88,767 -16.9%
Show Counterparty Name breakouts
Gondola Bio, LLC · Transition Service Aggrement 1.5 0.7 +114.3%
Selling, General & Administrative 531,225 288,931 +83.9%
Show Business Segments breakouts
Reportable Segment 531,225 288,931 +83.9%
Restructuring Settlement And Impairment Provisions 21,347 15,605 +36.8%
Show Business Segments breakouts
Reportable Segment 21,347 15,605 +36.8%
Total Costs & Expenses 1,025,487 814,875 +25.8%
Show Business Segments breakouts
Reportable Segment 1,025,487 814,875 +25.8%
Operating Income -523,411 -592,973 +11.7%
Show Business Segments breakouts
Reportable Segment -523,411 -592,973 +11.7%
Interest Income 19,854 17,249 +15.1%
Show Business Segments breakouts
Reportable Segment 19,854 17,249 +15.1%
Interest Expense -53,103 -90,991 +41.6%
Show Business Segments breakouts
Reportable Segment -53,103 -90,991 +41.6%
Noncash Interest Expense On Deferred Royalty Obligations -125,138 -8,299 -1407.9%
Show Business Segments breakouts
Reportable Segment -125,138 -8,299 -1407.9%
Reportable Segment · Related Party -10,944 — —
Show Related Party Transactions By Related Party breakouts
Related Party -10,944 — —
Gains Losses On Extinguishment Of Debt -21,155 -26,590 +20.4%
Show Business Segments breakouts
Reportable Segment -21,155 -26,590 +20.4%
Income Loss From Equity Method Investments -72,608 -31,183 -132.8%
Show Business Segments breakouts
Reportable Segment -72,608 -31,183 -132.8%
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts
BridgeBio Oncology Therapeutics, Inc. -37.5 — —
Gondola Bio, LLC -35.1 — —
Other Non-Operating Income (Expense) 43,058 12,272 +250.9%
Show Business Segments breakouts
Reportable Segment 43,058 12,272 +250.9%
Non-Operating Income (Expense) -209,092 50,779 -511.8%
Show Business Segments breakouts
Reportable Segment -209,092 50,779 -511.8%
Income Before Taxes -732,503 -542,194 -35.1%
Show Business Segments breakouts
Reportable Segment -732,503 -542,194 -35.1%
Income Tax Expense (Benefit) 435 1,153 -62.3%
Show Business Segments breakouts
Reportable Segment 435 1,153 -62.3%
Net Income -732,938 -543,347 -34.9%
Show Business Segments breakouts
Reportable Segment -732,938 -543,347 -34.9%
Net Income Loss Attributable To Noncontrolling Interest 8,007 7,585 +5.6%
Show Business Segments breakouts
Reportable Segment 8,007 7,585 +5.6%
Net Income Loss Available To Common Stockholders Basic -724,931 -535,762 -35.3%
Show Business Segments breakouts
Reportable Segment -724,931 -535,762 -35.3%
EPS (Basic) -3.78 -2.88 -31.2%
EPS (Diluted) -3.78 -2.88 -31.2%
Wtd Avg Shares (Basic) 191,527,482 186,075,873 +2.9%
Wtd Avg Shares (Diluted) 191,527,482 186,075,873 +2.9%
Operating Expenses (FY) — — —
Show Counterparty Name breakouts
BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement 0.5 0.7 -28.6%
Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement 5.1 0.8 +537.5%
Comprehensive Income -724,927 -535,785 -35.3%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 570,119 681,101 -16.3%
Available For Sale Securities Debt Securities Current 17,363 — —
Accounts Receivable 139,444 4,722 +2853.1%
Show Counterparty Name breakouts
Alexion License Agreements 0.2 0.6 -66.7%
Bayer 5 — —
Inventory 26,753 — —
Prepaid Expenses & Other Current Assets 44,070 34,869 +26.4%
Show Counterparty Name breakouts
BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement 0.6 0.5 +20.0%
Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement 4.5 3.2 +40.6%
Total Current Assets 797,749 720,692 +10.7%
Non-Current Assets
Property, Plant & Equipment 5,366 7,011 -23.5%
Operating Lease Right-of-Use Assets 8,149 5,767 +41.3%
Other Non-Current Assets 16,712 18,195 -8.2%
Show Counterparty Name breakouts
BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement 7.8 — —
Total Assets 936,025 919,338 +1.8%
Intangible Assets 28,077 23,926 +17.3%
Other Assets
Equity Method Investments 79,972 143,747 -44.4%
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts
BridgeBio Oncology Therapeutics, Inc. 72.5 102.2 -29.1%
Gondola Bio, LLC 6.4 41.5 -84.6%
Intangible Assets Net Excluding Goodwill 28,077 23,926 +17.3%
Current Liabilities
Accounts Payable 36,228 9,618 +276.7%
Employee Related Liabilities Current 76,703 58,329 +31.5%
Accrued Research And Development Liabilities Current 41,436 34,272 +20.9%
Operating Lease Liability Current 6,192 4,506 +37.4%
Deferred Revenue (Current) 7,190 14,604 -50.8%
Show Product Lines breakouts
Research and Development Services · Bayer 0.8 1.3 -38.5%
Show Counterparty Name breakouts
Alexion License Agreements 1 3 -66.7%
Kyowa Kirin Co., Ltd 5.4 10.3 -47.6%
Other Liabilities Current 120,222 33,071 +263.5%
Show Counterparty Name breakouts
Gondola Bio, LLC · Transition Service Aggrement 1.5 1.2 +25.0%
Show Related Party Transactions By Related Party breakouts
Related Party 2,003 — —
Total Current Liabilities 287,971 154,400 +86.5%
Non-Current Liabilities
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
2027 Notes, net 547,015 545,173 +0.3%
2029 Notes, net 740,890 738,872 +0.3%
2031 Notes, net 564,565 — —
Operating Lease Liabilities 3,811 4,696 -18.8%
Contract With Customer Liability Noncurrent 13,080 17,095 -23.5%
Show Product Lines breakouts
Research and Development Services · Bayer 2.1 2.2 -4.5%
Show Counterparty Name breakouts
Alexion License Agreements 1.8 — —
Kyowa Kirin Co., Ltd 9.2 14.9 -38.3%
Other Non-Current Liabilities 244 286 -14.7%
Total Liabilities 3,012,606 2,376,950 +26.7%
Long-Term Debt 2,007,337 — —
Show Debt Instrument breakouts
2027 Notes, net 570,625 — —
2027 Notes, net · Convertible Debt 547,015 545,173 +0.3%
2029 Notes, net 806,366 — —
2029 Notes, net · Convertible Debt 740,890 738,872 +0.3%
2031 Notes, net 630,346 — —
2031 Notes, net · Convertible Debt 564,565 — —
Other Liabilities
Deferred Royalty Obligation Net 855,030 479,091 +78.5%
Show Related Party Transactions By Related Party breakouts
Related Party 204,650 — —
Show Type Of Arrangement breakouts
Funding Agreement 548,055 479,091 +14.4%
Royalty Purchase Agreement 306,975 — —
Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests -570 142 -501.4%
Stockholders' Equity
Common Stock 202 196 +3.1%
Treasury Stock Common Value -323,276 -275,000 -17.6%
Additional Paid-In Capital 2,057,646 1,903,155 +8.1%
Accumulated Other Comprehensive Income 12 8 +50.0%
Retained Earnings -3,821,194 -3,096,263 -23.4%
Total Stockholders' Equity -2,086,610 -1,467,904 -42.1%
Minority Interest 10,599 10,150 +4.4%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2,076,011 -1,457,754 -42.4%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 12 8 +50.0%
Additional Paid In Capital 2,057,646 1,903,155 +8.1%
Common Stock 202 196 +3.1%
Noncontrolling Interest 10,599 10,150 +4.4%
Parent -2,086,610 -1,467,904 -42.1%
Retained Earnings -3,821,194 -3,096,263 -23.4%
Treasury Stock Common -323,276 -275,000 -17.6%
Total Liabilities & Equity 936,025 919,338 +1.8%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Stock-Based Compensation 133,024 95,800 +38.9%
Amortization Of Financing Costs And Discounts 5,967 7,464 -20.1%
Show Debt Instrument breakouts
2027 Notes, net · Convertible Debt 1,842 1,794 +2.7%
2029 Notes, net · Convertible Debt 2,018 1,967 +2.6%
2031 Notes, net · Convertible Debt 1,599 — —
Show Long-Term Debt Type breakouts
Convertible Debt 5,459 3,761 +45.1%
Depreciation & Amortization 5,434 6,075 -10.6%
Operating Lease Right Of Use Asset Amortization Expense 4,902 4,110 +19.3%
Embedded Derivative Gain Loss On Embedded Derivative Net -19,652 -1,550 -1167.9%
Noncash Income Loss From Equity Method Investments -8,833 — —
Other Non-Cash Items -1,651 -935 -76.6%
Change in Accounts Receivable -134,722 -2,971 -4434.6%
Change in Inventory -25,307 — —
Change in Prepaid & Other Assets -8,777 -13,918 +36.9%
Increase Decrease In Other Operating Assets 1,113 1,542 -27.8%
Change in Accounts Payable 26,609 1,512 +1659.9%
Increase Decrease In Employee Related Liabilities 23,022 16,986 +35.5%
Increase Decrease In Accrued Research And Development Liabilities 7,163 8,729 -17.9%
Increase Decrease In Operating Lease Liability -6,547 -5,902 -10.9%
Increase Decrease In Deferred Revenue -11,428 21,875 -152.2%
Increase Decrease In Other Operating Liabilities 77,810 4,189 +1757.5%
Show Related Party Transactions By Related Party breakouts
Related Party 2,003 — —
Net Cash from Operations -445,910 -520,726 +14.4%
Change in Deferred Revenue 150.1 — —
Investing Activities
Purchases of Investments -28,197 -93,811 +69.9%
Proceeds From Sale And Maturity Of Available For Sale Securities 11,000 95,000 -88.4%
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital 2,302 25,682 -91.0%
Payments To Acquire Intangible Assets -8,495 -7,975 -6.5%
Capital Expenditures -1,097 -933 -17.6%
Net Cash from Investing -24,487 60,781 -140.3%
Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest -5,594 -5,819 +3.9%
Financing Activities
Proceeds From Convertible Debt (FY) — — —
Show Debt Instrument breakouts
2031 Notes, net 575,000 — —
Debt Issuance Costs (FY) — — —
Show Debt Instrument breakouts
2031 Notes, net -12,034 — —
Share Repurchases -48,276 — —
Proceeds From Royalty Obligation (FY) — — —
Show Type Of Arrangement breakouts
Royalty Interest Purchase and Sale Agreement 300,000 — —
Issuance Costs And Discounts Associated With Royalty Obligation (FY) — — —
Show Type Of Arrangement breakouts
Royalty Interest Purchase and Sale Agreement -3,010 — —
Repayments Of Lines Of Credit -459,000 -473,417 +3.0%
Payment Of Deferred Royalty Obligation -15,460 — —
Show Related Party Transactions By Related Party breakouts
Related Party -2,295 — —
Proceeds From Stock Plans 6,414 4,502 +42.5%
Proceeds From Stock Options Exercised 27,735 3,656 +658.6%
Proceeds From Payments To Minority Shareholders 2,150 — —
Tax Withholding for Share Compensation -14,226 -7,526 -89.0%
Net Cash from Financing 359,293 748,457 -52.0%
Supplemental
Interest Paid 43,670 91,342 -52.2%
Income Taxes Paid 1,198 — —
Unpaid Capital Expenditures 43 279 -84.6%
Income Taxes Paid 1,198 — —
Other Cash Flow
Net Change in Cash -111,104 288,512 -138.5%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 572,140 683,244 -16.3%
Restricted Cash Current 550 126 +336.5%
Restricted Cash Noncurrent 1,471 2,017 -27.1%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 572,140 683,244 -16.3%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key